The authors regret the mistake in Table 2: Targeted therapies for advanced biliary tract cancers: Median overall survival in the HERIZON-BTC-01 phase 2 trial of zanidatamab was 15.5 months in the HER2+ population, while the table shows 5.5 months. In the Lancet Oncology publication cited in the manuscript OS was not mature, and the OS of 15.5 months was reported at ASCO 2024.1 The authors would like to apologise for any inconvenience caused.
Correction to “New systemic treatment paradigms in advanced biliary tract cancer and variations in patient access across Europe” [The Lancet Regional Health – Europe, volume 50, March 2025, 101170] (The Lancet Regional Health - Europe (2025) 50, (S2666776224003399), (10.1016/j.lanepe.2024.101170)) / Rimassa, L.; Lamarca, A.; O'Kane, G. M.; Edeline, J.; Mcnamara, M. G.; Vogel, A.; Fassan, M.; Forner, A.; Kendall, T.; Adeva, J.; Casadei-Gardini, A.; Fornaro, L.; Hollebecque, A.; Lowery, M. A.; Macarulla, T.; Malka, D.; Mariamidze, E.; Niger, M.; Ustav, A.; Bridgewater, J.; Macias, R. I. R.; Braconi, C.. - In: THE LANCET REGIONAL HEALTH. EUROPE. - ISSN 2666-7762. - 53:(2025). [10.1016/j.lanepe.2025.101306]
Correction to “New systemic treatment paradigms in advanced biliary tract cancer and variations in patient access across Europe” [The Lancet Regional Health – Europe, volume 50, March 2025, 101170] (The Lancet Regional Health - Europe (2025) 50, (S2666776224003399), (10.1016/j.lanepe.2024.101170))
Lamarca A.Secondo
;Casadei-Gardini A.;
2025-01-01
Abstract
The authors regret the mistake in Table 2: Targeted therapies for advanced biliary tract cancers: Median overall survival in the HERIZON-BTC-01 phase 2 trial of zanidatamab was 15.5 months in the HER2+ population, while the table shows 5.5 months. In the Lancet Oncology publication cited in the manuscript OS was not mature, and the OS of 15.5 months was reported at ASCO 2024.1 The authors would like to apologise for any inconvenience caused.| File | Dimensione | Formato | |
|---|---|---|---|
|
1-s2.0-S2666776225000973-main.pdf
accesso aperto
Tipologia:
PDF editoriale (versione pubblicata dall'editore)
Licenza:
Licenza OA dell'editore
Dimensione
98.44 kB
Formato
Adobe PDF
|
98.44 kB | Adobe PDF | Visualizza/Apri |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
